AAAAAA
Results:
1-13
|
Results: 13
Authors:
Barbour, V
Citation: V. Barbour, Imatinib for chronic myeloid leukaemia: a NICE mess, LANCET, 358(9292), 2001, pp. 1478-1478
Authors:
Barbour, V
Citation: V. Barbour, Immunology approaches the bedside, LANCET, 357(9270), 2001, pp. 1728-1728
Authors:
Barbour, V
Citation: V. Barbour, Time to concentrate on DNA control, LANCET, 357(9262), 2001, pp. 1102-1102
Authors:
Barbour, V
Citation: V. Barbour, Retaining trust, LANCET, 357(9253), 2001, pp. 328-328
Authors:
Ramamurthy, L
Barbour, V
Tuckfield, A
Clouston, DR
Topham, D
Cunningham, JM
Jane, SM
Citation: L. Ramamurthy et al., Targeted disruption of the CP2 gene, a member of the NTF family of transcription factors, J BIOL CHEM, 276(11), 2001, pp. 7836-7842
Authors:
Kleinert, S
Barbour, V
Citation: S. Kleinert et V. Barbour, One world, many voices, LANCET, 356, 2000, pp. NIL_1-NIL_1
Authors:
Barbour, V
Kleinert, S
McMenemy, MC
Mullan, Z
Osmond, R
Simini, B
Weber, W
Davies, R
Duff, E
Citation: V. Barbour et al., Meg Campbell, LANCET, 356, 2000, pp. COVER2-COVER2
Authors:
Barbour, V
Kleinert, S
Citation: V. Barbour et S. Kleinert, Changing perspective, LANCET, 356(9248), 2000, pp. 2118-2118
Authors:
Barbour, V
Citation: V. Barbour, Long-term safety now priority in leukaemia therapy, LANCET, 355(9211), 2000, pp. 1247-1247
Authors:
Barbour, V
Citation: V. Barbour, Haematology for non-haematologists, LANCET, 355(9210), 2000, pp. 1118-1118
Authors:
Barbour, V
Citation: V. Barbour, The balance of risk and benefit in gene-therapy trials, LANCET, 355(9201), 2000, pp. 384-384
Authors:
Barbour, V
Citation: V. Barbour, Gene therapy advances greeted positively, LANCET, 354(9195), 1999, pp. 2057-2057
Authors:
Barbour, V
Citation: V. Barbour, Therapeutic immunomodulation branches out, LANCET, 354(9187), 1999, pp. 1363-1363
Risultati:
1-13
|